Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Phase 2
Terminated
- Conditions
- Head and Neck Cancer
- Interventions
- Biological: filgrastimBiological: pegfilgrastimProcedure: conventional surgeryRadiation: radiation therapy
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 4
- Registration Number
- NCT00352118
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma
- Interventions
- Procedure: peripheral blood stem cell transplantationRadiation: irradiation therapyBiological: G-CSF
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 473
- Registration Number
- NCT00345865
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
Not Applicable
Completed
- Conditions
- Sarcoma
- Interventions
- Biological: pegfilgrastimProcedure: conventional surgeryRadiation: fludeoxyglucose F 18
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 70
- Registration Number
- NCT00346125
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 2
Terminated
- Conditions
- Peritoneal Cavity CancerFallopian Tube CancerOvarian Cancer
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 7
- Registration Number
- NCT00331422
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Phase 2
Completed
- Conditions
- Ovarian CancerBreast CancerEndometrial CancerCervical Cancer
- Interventions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT00319748
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Phase 2
Completed
- Conditions
- Acute Lymphocytic LeukemiaMDSChronic Lymphocytic LeukemiaNon-Hodgkin's LymphomaLymphomaRefractory AnemiaMyelodysplastic SyndromesChronic Myelogenous LeukemiaMyelofibrosisProlymphocytic Leukemia
- Interventions
- Biological: filgrastimProcedure: umbilical cord blood transplantationRadiation: total-body irradiation
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 213
- Registration Number
- NCT00309842
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Phase 2
Completed
- Conditions
- LeukemiaLymphomaMyelodysplastic SyndromesMyeloproliferative Disorders
- Interventions
- Biological: anti-thymocyte globulinProcedure: umbilical cord blood transplantationRadiation: total body irradiation
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 295
- Registration Number
- NCT00305682
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Phase 2
Terminated
- Conditions
- Kidney CancerLeukemiaLymphomaMultiple MyelomaPlasma Cell NeoplasmMyelodysplastic Syndromes
- Interventions
- Biological: anti-thymocyte globulinProcedure: stem cell transplantationRadiation: total body irradiation
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 342
- Registration Number
- NCT00303719
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
Phase 1
Completed
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- Biological: aldesleukinBiological: natural killer cellsBiological: ThymoglobulinProcedure: allogeneic hematopoietic stem cell transplantationRadiation: total body irradiation
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 50
- Registration Number
- NCT00303667
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer
Phase 1
Terminated
- Conditions
- LeukemiaMyelodysplastic SyndromesMyeloproliferative DisordersLymphoma
- Interventions
- Procedure: umbilical cord blood transplantation
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 12
- Registration Number
- NCT00295880
© Copyright 2025. All Rights Reserved by MedPath